MV Ramana

Dr Reddy's Launched Remdesivir as Redyx for Indian Market

The launch is part of a licensing agreement with Gilead Sciences Inc that grants Dr Reddy's the right to register, manufacture and sell Remdesivir, a potential treatment for COVID-19, in 127 countries including India.